A proposed $7.25 billion settlement designed to cap future Roundup cancer claims is drawing sharp legal challenges from plaintiffs' attorneys who say the deal shortchanges victims, even as the Supreme Court prepares to issue a ruling that could reshape the entire litigation landscape by the end of June.
The dual-track legal strategy from Bayer, which acquired Monsanto and its flagship weedkiller, amounts to a corporate pincer movement: win at the Supreme Court and gut the legal basis for state-level lawsuits, or lock future claimants into a settlement with capped payouts over two decades. Either way, the company walks away from the open-ended liability that has already cost it roughly $10 billion in prior settlements and produced verdicts running into the billions.
For tens of thousands of Americans who allege Roundup gave them cancer, the next few weeks will determine whether they retain meaningful access to the courts or find the doors closing on both fronts.
Bayer's proposed nationwide class settlement would distribute up to $7.25 billion in capped annual payments spread over 21 years, as USA Today reported. The structure would cover claims that could continue regardless of how the Supreme Court rules on federal preemption.
Plaintiffs' lawyers challenging the deal argue that it binds future claimants to terms negotiated without their meaningful participation. The objection is familiar in mass-tort law: class settlements that prioritize finality for the defendant can leave individual plaintiffs with fractions of what they might win at trial.
Bayer faces roughly 65,000 active claims in state and federal courts, the New York Post reported, with the total number of Roundup claims exceeding 100,000. The company has already paid about $10 billion to resolve most lawsuits pending as of 2020, but new cases keep arriving. Bayer set aside $16 billion overall to handle Roundup litigation.
The sheer volume of claims explains why the company wants a global resolution. But the settlement's critics see a deal structured to cap corporate exposure at a level far below what juries have been willing to award.
Running parallel to the settlement fight is Bayer's appeal of a $1.25 million Missouri jury verdict in favor of John Durnell, who alleged that Roundup exposure caused his non-Hodgkin's lymphoma and that Monsanto failed to warn consumers about cancer risks.
The legal question before the justices is narrow but carries enormous consequences: does federal pesticide law, specifically the EPA's approval of Roundup's labeling, preempt state-level failure-to-warn lawsuits? If the Court says yes, plaintiffs who relied on state consumer-protection and tort law to bring claims would lose their primary legal theory.
Bayer's position is straightforward. The EPA has repeatedly found that glyphosate, the active ingredient in Roundup, is "not likely to be carcinogenic in humans." The agency approved labels that contained no cancer warnings. Punishing a company under state law for following federal labeling requirements, Bayer argues, contradicts the supremacy of federal regulation. The Supreme Court's decision to take up the fight over state cancer warnings on pesticide labels signaled that at least four justices thought the preemption argument deserved a full hearing.
U.S. Solicitor General D. John Sauer backed the company's position in filings, stating that "EPA has repeatedly determined that glyphosate is not likely to be carcinogenic in humans, and the agency has repeatedly approved Roundup labels that did not contain cancer warnings."
Oral arguments revealed a bench wrestling with the tension between federal regulatory authority and state-level consumer protection. AP News reported that the justices appeared split on whether EPA approval should function as a litigation shield.
Chief Justice John Roberts pressed the government's lawyer with a pointed question:
"Throughout that long process, in response to information that suggests there is a risk that's not on the label, the states cannot do anything?"
That question cut to the heart of the case. If federal preemption blocks state lawsuits, then consumers who develop cancer after using an EPA-approved product would have limited recourse, even if new scientific evidence later suggested the label was inadequate. For conservatives who value federalism and state sovereignty, the case presents an uncomfortable crosscurrent: corporate regulatory compliance versus the traditional police power of states to protect their citizens' health.
The Court is expected to hand down its decision by the end of June, Breitbart reported, a timeline that places the ruling squarely in the final weeks of the current term.
Bayer CEO Bill Anderson has been candid about the company's approach. In a statement reported by Newsmax, Anderson said:
"The proposed class settlement agreement, together with the Supreme Court case, provides an essential path out of the litigation uncertainty."
The company described the two tracks as "mutually reinforcing steps" to contain the litigation. A favorable Supreme Court ruling would eliminate future failure-to-warn claims rooted in state law, while the settlement would mop up claims that survive regardless of the preemption question. Anderson also stated bluntly that "it is time for the US legal system to establish that companies should not be punished under state laws for complying with federal warning label requirements."
Bayer has gone further, warning that it might have to consider pulling glyphosate from U.S. agricultural markets entirely if the lawsuits persist. That threat carries real weight. Roundup is the most widely used herbicide in American agriculture, and removing it would ripple through farming operations nationwide.
Attorneys challenging the proposed settlement argue that capping payouts over a 21-year window undervalues the claims of people who may develop non-Hodgkin's lymphoma years from now. The structure of mass-tort class settlements has drawn scrutiny in other major cases. Courts have grappled with similar tensions in litigation against tech companies facing addiction lawsuits, where the question of how to value future harm against present corporate certainty runs through every negotiation.
The objectors want the court overseeing the settlement to reject it or demand substantially different terms. They argue that binding future claimants to a deal negotiated primarily to serve Bayer's need for finality violates basic principles of due process in class-action law.
Authorities have not publicly confirmed whether the settlement court will rule before or after the Supreme Court issues its preemption decision. The sequencing matters enormously. A preemption ruling in Bayer's favor would weaken the bargaining position of settlement objectors, while a ruling against Bayer would strengthen the hand of every plaintiff still in the litigation pipeline.
This case sits at the intersection of federal regulatory power, corporate liability, and access to courts. If the Supreme Court rules that EPA label approval preempts state tort claims, the precedent would extend well beyond Roundup. Any manufacturer of a federally regulated product could argue that compliance with agency labeling requirements immunizes it from state-level lawsuits. That principle would reshape liability exposure across industries, from pharmaceuticals to consumer chemicals.
The scale of the litigation is staggering. More than 100,000 claims, $16 billion in reserves, multibillion-dollar jury verdicts, and a proposed settlement worth $7.25 billion over two decades. The financial magnitude rivals the largest class-action disputes involving major corporations in recent memory.
Investigators and regulators will need to determine whether the current scientific consensus on glyphosate holds up as more long-term exposure data becomes available. The EPA's position that glyphosate is not likely carcinogenic stands in tension with a 2015 finding by the World Health Organization's International Agency for Research on Cancer, which classified it as "probably carcinogenic." That split has fueled the litigation from the start.
Bayer finds itself in a position where every path forward carries significant cost. Winning at the Supreme Court would eliminate a category of claims but would not erase the reputational damage or the billions already spent. Losing would leave the company exposed to an open-ended stream of jury trials across dozens of state courts, each with its own rules and sympathies.
The settlement, if approved over objections, would provide the certainty Bayer craves. But for plaintiffs who believe a jury would award them far more than a capped settlement payout, the deal looks like a ceiling imposed without their consent. The tension between institutional defendants facing sweeping liability and individual claimants seeking their day in court is as old as mass-tort law itself.
No public results have been released about how the settlement court will weigh the objections. The Supreme Court's preemption ruling will arrive first or close to the same time, and its outcome will shape everything that follows.
When the government tells you a product is safe, approves the label, and then tens of thousands of people get sick, someone has to answer for it. The question heading to the Court is whether that someone is the company, the states, or nobody at all.
